Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease
Authors:
- Marc MorissetteMMMarc Morissette
- Mélissa CôtéMCMélissa Côté
- Denis SouletDSDenis Soulet
- Thérèse Di PaoloTPThérèse Di Paolo
- 1 March 2013
- journal article
- research article
- Published by Elsevier in Neurobiology of Aging
- Vol. 34 (3) , 887-901
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research
This publication has 38 references indexed in Scilit:
- Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson’s diseaseNeuropharmacology, 2011
- Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a Novel GPR30-Dependent MechanismACS Chemical Neuroscience, 2011
- Neuroprotective actions of sex steroids in Parkinson’s diseaseFrontiers in Neuroendocrinology, 2009
- In vivo effects of a GPR30 antagonistNature Chemical Biology, 2009
- Virtual and biomolecular screening converge on a selective agonist for GPR30Nature Chemical Biology, 2006
- Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ERα agonistNeuropharmacology, 2004
- Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 miceSynapse, 2001
- Short-term effects of high-dose 17β-estradiol in postmenopausal PD patientsNeurology, 1999
- 17β-estradiol at a physiological dose acutely increases dopamine turnover in rat brainEuropean Journal of Pharmacology, 1985
- Estimation of nuclear population from microtome sectionsThe Anatomical Record, 1946